At 11:00 am ET today (November 1, 2021), the results will be launched for research that studied Incidence of blood embolisms in brain after Johnson & & Johnson/Janssen COVID-19 vaccination.
What The Study Did: Resarchers compared post-Ad26. COV2.S (Johnson & & Johnson/Janssen) vaccination cerebral venous sinus thrombosis (CVST, an embolism in the brain) rates with prepandemic rates to estimate postvaccination CVST danger. The rate of this unusual adverse impact should be considered in the context of the effectiveness of the vaccine in preventing COVID-19.
Recommendation: “Age- and Sex-Specific Incidence of Cerebral Venous Sinus Thrombosis Associated With Ad26.COV2.S COVID-19 Vaccination” by Aneel A. Ashrani, MD, MS; Daniel J. Crusan, BS; Tanya Petterson, MS; Kent Bailey, PhD and John A. Heit, MD, 1 November 2021, JAMA Internal Medicine.DOI: 10.1001/ jamainternmed.2021.6352.
Authors: Aneel A. Ashrani, M.D., M.S., of the Mayo Clinic in Rochester, Minnesota, is the corresponding author.
Link: JAMA Internal Medicine
The study found a “substantially greater” brain blood embolism (cerebral venous sinus apoplexy/ CVST) incidence rate in individuals after vaccination with the Johnson & & Johnson COVID-19 vaccine. The highest threat was in ladies in between the ages of 30 and 49, with a lot of CVST events occurring within 15 days of vaccination.
Although this is a major adverse effects, the authors warn that “the higher rate of this rare adverse result must be considered in the context of the effectiveness of the vaccine in preventing COVID-19.”
By JAMA Network
November 1, 2021
